公开(公告)号：US07645450B2

公开(公告)日：2010-01-12

申请号：US11722094

申请日：2005-12-29

申请人： Tae Hyoung Yoo ,  Moo Young Song ,  Chang Seok Kim ,  Sang Koo Park ,  Kang In Na ,  Byung Kyu Lee ,  Heui Il Kang

发明人： Tae Hyoung Yoo ,  Moo Young Song ,  Chang Seok Kim ,  Sang Koo Park ,  Kang In Na ,  Byung Kyu Lee ,  Heui Il Kang

IPC分类号： A61K39/395

CPC分类号： C07K16/241 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： Humanized antibodies specifically binding to hTNF-α are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-α-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.

摘要翻译： 通过CDR（互补决定区）接枝方法由小鼠单克隆抗体制备与hTNF-α特异性结合的人源化抗体，它们显示与原始小鼠单克隆抗体相似的抗原结合亲和力，并且显着低的免疫原性。 因此，人源化抗体可以有效地用于治疗hTNF-α相关疾病如类风湿性关节炎，克罗恩病，牛皮癣关节炎，银屑病，败血病，哮喘，韦格纳肉芽肿病，炎症和强直性脊柱炎。

公开(公告)号：US20070249658A1

公开(公告)日：2007-10-25

申请号：US11574406

申请日：2005-09-03

申请人： Jae-Gyu Kim ,  Byung-Nak Ahn ,  Hyouk-Woo Lee ,  Suk-Won Yoon ,  Young-Ae Yoon ,  Hyun-Ho Choi ,  Heui-Il Kang

发明人： Jae-Gyu Kim ,  Byung-Nak Ahn ,  Hyouk-Woo Lee ,  Suk-Won Yoon ,  Young-Ae Yoon ,  Hyun-Ho Choi ,  Heui-Il Kang

IPC分类号： A61K31/44 ,  A61K31/47 ,  C07D217/00 ,  C07D403/00

CPC分类号： C07D471/04

摘要： The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.

摘要翻译： 本发明提供新颖的吡咯并[3,2-c]吡啶衍生物或其药学上可接受的盐，其制备方法和包含其的组合物。 本发明的吡咯并[3,2-c]吡啶衍生物或其药学上可接受的盐具有优异的质子泵抑制作用，具有获得可逆质子泵抑制效果的能力。

公开(公告)号：US20020071864A1

公开(公告)日：2002-06-13

申请号：US10016821

申请日：2001-12-07

申请人： Yuhan Corporation

发明人： Hyun-Soo Kim ,  Young-Joon Park ,  Dae-Sik Kang

IPC分类号： A61K009/20

CPC分类号： A61K31/4178 ,  A61K9/0007 ,  A61K9/0056 ,  A61K31/167 ,  A61K31/426 ,  A61K31/439 ,  A61K31/4422 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/519

摘要： The present invention relates to a rapidly disintegrable tablet for oral administration, which disintegrates in the oral cavity within 60 seconds, consisting essentially of (i) a therapeutically effective amount of an active ingredient, (ii) spray-dried mannitol, of which at least 80% has an average particle size over 100 nullm, (iii) crospovidone, and (iv) one or more pharmaceutically acceptable excipients, the tablet containing no microcrystalline cellulose.

摘要翻译： 本发明涉及用于口服给药的快速崩解片剂，其在60秒内在口腔内崩解，基本上由（i）治疗有效量的活性成分，（ii）喷雾干燥的甘露醇至少 80％的平均粒径超过100μm，（iii）交聚维酮，和（iv）一种或多种药学上可接受的赋形剂，该片不含微晶纤维素。

公开(公告)号：US5750531A

公开(公告)日：1998-05-12

申请号：US776220

申请日：1997-01-23

申请人： Jong Wook Lee ,  Jeong Seok Chae ,  Chang Seop Kim ,  Jae Kyu Kim ,  Dae Sung Lim ,  Moon Kyu Shon ,  Yeon Shik Choi ,  Sang Ho Lee

发明人： Jong Wook Lee ,  Jeong Seok Chae ,  Chang Seop Kim ,  Jae Kyu Kim ,  Dae Sung Lim ,  Moon Kyu Shon ,  Yeon Shik Choi ,  Sang Ho Lee

IPC分类号： C07D239/42 ,  A61K31/505 ,  A61K31/506 ,  A61P1/04 ,  A61P5/00 ,  A61P43/00 ,  C07D401/04 ,  C07D409/14 ,  C07D495/04 ,  C07D239/02 ,  C07D239/70

CPC分类号： C07D401/04 ,  C07D495/04

摘要： The present invention relates to novel pyrimidine derivatives of the formulae (I-1) and (I-2) and pharmaceutically acceptable salts thereof which possess an excellent anti-secretory activity, pharmaceutical compositions containing same as an active ingredient, their novel intermediates, and processes for the preparation thereof: ##STR1## wherein: R.sub.4 and R.sub.5, which may be the same or different, are independently hydrogen or a C.sub.1 -C.sub.3 alkyl group, or jointly form a cyclopentyl or cyclohexyl ring; A is a group of formula(II): ##STR2## wherein R.sub.1 and R.sub.2 are, independently of each other, hydrogen or a C.sub.1 -C.sub.3 alkyl group, and R.sub.3 is hydrogen, a C.sub.1 -C.sub.3 alkyl group or a halogen; and B is 1-(substituted)-1,2,3,4-tetrahydroisoquinolin-2-yl of formula (III-1) or 7-(substituted)-4,5,6,7-tetrahydrothieno�2,3-c!pyridin-6-yl of formula (III-2) ##STR3## wherein R.sub.6 is hydrogen or a C.sub.1 -C.sub.3 alkyl group.

摘要翻译： PCT No.PCT / KR95 / 00105 Sec。 371日期1997年1月23日 102（e）日期1997年1月23日PCT提交1995年8月10日PCT公布。 出版物WO96 / 05177 日期1996年2月22日本发明涉及具有优异抗分泌活性的式（I-1）和（I-2）的新颖的嘧啶衍生物及其药学上可接受的盐，其含有作为活性成分的药物组合物， （I-1）其中：R 4和R 5可以相同或不同，独立地是氢或C 1 -C 3烷基 或共同形成环戊基或环己基环; A是式（II）的基团：其中R 1和R 2彼此独立地为氢或C 1 -C 3烷基，R 3为氢，C 1 -C 3烷基或卤素 ; 和B是式（III-1）的1-（取代的）-1,2,3,4-四氢异喹啉-2-基或7-（取代的）-4,5,6,7-四氢噻吩并〔2,3- c]吡啶-6-基，其中R 6是氢或C 1 -C 3烷基。

公开(公告)号：US20240174636A1

公开(公告)日：2024-05-30

申请号：US18551894

申请日：2022-03-22

申请人： YUHAN CORPORATION

发明人： Gyu-Jin LEE ,  Eui-Chul LEE ,  Sol PARK ,  Dong-Hoon LEE ,  Su-Hwa KIM ,  Jong-Suk PARK ,  Ho-Woong KANG ,  Hyun-Sik YUN

IPC分类号： C07D401/12 ,  A61K31/4709 ,  A61K31/517 ,  C07D215/18 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D401/12 ,  A61K31/4709 ,  A61K31/517 ,  C07D215/18 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04

摘要： Provided are a compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof not only has excellent inhibitory activity against indoleamine 2,3-dioxygenase (IDO) but also exhibits remarkably high in vivo exposure upon oral administration and therefore the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with IDO.

公开(公告)号：US11981658B2

公开(公告)日：2024-05-14

申请号：US17822450

申请日：2022-08-26

申请人： YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

发明人： Byoungmoon Lee ,  Hyunjoo Lee ,  Gyu Jin Lee ,  Su Bin Choi ,  Sol Park ,  Heejun Kim ,  Misong Kim ,  Young Ae Yoon ,  Kwan Hoon Hyun ,  Tae Kyun Kim ,  Jae Young Sim ,  Marian C. Bryan ,  Scott Kuduk ,  James Campbell Robertson

IPC分类号： C07D401/14

CPC分类号： C07D401/14

摘要： Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US11945798B2

公开(公告)日：2024-04-02

申请号：US17822438

申请日：2022-08-26

申请人： YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

发明人： Hyunjoo Lee ,  Su Bin Choi ,  Young Ae Yoon ,  Kwan Hoon Hyun ,  Jae Young Sim ,  Marian C. Bryan ,  Scott Kuduk ,  James Campbell Robertson ,  Jaekyoo Lee ,  Paresh Devidas Salgaonkar ,  Byung-Chul Suh ,  Jong Sung Koh ,  So Young Hwang

IPC分类号： C07D401/14 ,  C07D413/14

CPC分类号： C07D401/14 ,  C07D413/14

摘要： Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US11850248B2

公开(公告)日：2023-12-26

申请号：US15931626

申请日：2020-05-14

申请人： Janssen Biotech, Inc. ,  Yuhan Corporation

发明人： Seonmi Kang ,  Sewoong Oh

IPC分类号： A61K31/5377 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K31/5377 ,  A61P35/00 ,  A61P35/04

摘要： The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).

公开(公告)号：US11713308B2

公开(公告)日：2023-08-01

申请号：US17368738

申请日：2021-07-06

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Eui Chul Lee ,  Sol Park ,  Hyok Jun Cho ,  Cheol Hee Lim ,  So Young Kim ,  Hyun Ho Choi ,  Da Na Jeong ,  Na Yeon Yang ,  Na Ry Ha

IPC分类号： C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

CPC分类号： C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

摘要： The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11708362B2

公开(公告)日：2023-07-25

申请号：US17704718

申请日：2022-03-25

申请人： Yuhan Corporation

发明人： Sang-Ho Oh ,  Ja-Heouk Khoo ,  Jong-Chul Lim ,  Seong-Ran Lee ,  Hyun Ju ,  Woo-Seob Shin ,  Dae-Gyu Park ,  Su-Min Park ,  Yoon-Ah Hwang

IPC分类号： C07D413/14

CPC分类号： C07D413/14

摘要： The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.